Compare DexCom, Inc. (DXCM) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Xpeng Inc - ADR — how do they compare? DexCom, Inc. trades at $84.14 (market cap $31.86B), while Xpeng Inc - ADR trades at $9.89 (market cap $9.16B). The key difference: DexCom, Inc. is far larger — about 3.5× Xpeng Inc - ADR's market cap, and DexCom, Inc. is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Xpeng Inc - ADR for 80 Days on average.
| DXCM | XPEV | |
|---|---|---|
Market Cap | $31.86B | $9.16B |
Volume | 3,607,070 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $28.07 |
52-Week Low | $54.84 | $9.25 |
Typical Hold Time | 62 Days | 80 Days |
Enterprise Value | $31.32B | $11.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
XPeng (XPEV) trades at $9.90, up 3.34% with a bearish technical signal despite recent delivery growth. The company shows improving fundamentals with revenue surging to $76.72B in 2025 and narrowing losses, though it remains unprofitable with negative margins. Recent news highlights expansion into robotics and global vehicle launches, while analyst consensus remains bullish with a $17.55 price target representing 77% upside potential.
XPeng presents a high-risk, high-reward opportunity with strong revenue growth and technological innovation offset by persistent profitability challenges. The stock's current discount to analyst targets offers potential upside, but investors face risks from competitive pressures, execution challenges in new business lines, and ongoing losses that could pressure the balance sheet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
